东诚药业(002675.SZ)：氟[18F]思睿肽注射液上市申请获国家药品监督管理局受理

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (referred to as "Lannacheng"), has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of the investigational drug Fluorine-18 [18F] PSMA peptide injection [1] Group 1 - Lannacheng's Fluorine-18 [18F] PSMA peptide injection is a targeted radioactive diagnostic drug for in vivo imaging of prostate cancer patients with positive prostate-specific membrane antigen (PSMA) lesions [1] - The drug is intended for two specific patient groups: (1) prostate cancer patients suspected of having metastatic lesions who are about to undergo initial radical treatment; (2) prostate cancer patients with elevated serum prostate-specific antigen (PSA) levels suspected of biochemical recurrence [1]